Overview
XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.
Status:
Completed
Completed
Trial end date:
2008-12-01
2008-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of this trial is to assess the long-term safety and efficacy of XP13512 (Gabapentin Enacarbil) taken once daily for the treatment of patients suffering from Restless Legs Syndrome (RLS).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
XenoPort, Inc.Treatments:
Gabapentin
gamma-Aminobutyric Acid
Criteria
Inclusion Criteria:- Patients who have successfully completed one of the following studies: XP052 (110963
[NCT00298623]), XP053 (111460 [NCT00365352]), XP081 (111462 [NCT01332305]), and XP083
(111463 [NCT01332318]).
Exclusion Criteria:
- Subjects who, in the opinion of the Investigator, would be non-compliant with the
study visit schedule, procedures, or medication administration.